Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. - Wikidata - awgldk - TriplyDB

Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa.

Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa.

http://www.wikidata.org/entity/Q33935368

about

A novel approach to pharmacodynamic assessment of antimicrobial agents: new insights to dosing regimen design Elucidation of the Mode of Action of a New Antibacterial Compound Active against Staphylococcus aureus and Pseudomonas aeruginosa Probing the penetration of antimicrobial polymyxin lipopeptides into gram-negative bacteria Isolation and characterization of an antimicrobial lipopeptide produced by Paenibacillus ehimensis MA2012.Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models.Colistin-induced nephrotoxicity in mice involves the mitochondrial, death receptor, and endoplasmic reticulum pathways.Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model.Colistin in the 21st century.Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model.Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature.Multi-drug resistant gram negative infections and use of intravenous polymyxin B in critically ill children of developing country: retrospective cohort study.Novel rate-area-shape modeling approach to quantify bacterial killing and regrowth for in vitro static time-kill studies.Colistin and polymyxin B: peas in a pod, or chalk and cheese?Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula.Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance.Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model.Novel modeling framework to guide design of optimal dosing strategies for β-lactamase inhibitors.High performance liquid chromatography-mass spectrometry assay for polymyxin B1 and B2 in human plasma.Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rods Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design Synergistic killing of NDM-producing MDR Klebsiella pneumoniae by two 'old' antibiotics-polymyxin B and chloramphenicol.Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa.A validated ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of polymyxin B in mouse serum and epithelial lining fluid: application to pharmacokinetic studies Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosa Polymyxin B: similarities to and differences from colistin (polymyxin E).Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumannii The current state of multidrug-resistant gram-negative bacilli in North America.In Vitro Activity of Polymyxin B in Combination with Various Antibiotics against Extensively Drug-Resistant Enterobacter cloacae with Decreased Susceptibility to Polymyxin B.Polymyxins revisited.Comparative Pharmacokinetic Profiling of Different Polymyxin B Components.Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy.Combination antibiotic therapy for empiric and definitive treatment of gram-negative infections: insights from the Society of Infectious Diseases Pharmacists.The safety of polymyxin antibiotics.Polymyxin B versus colistin: an update.Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: part II Gram-negative bacteria.Dosing and Pharmacokinetics of Polymyxin B in Patients with Renal Insufficiency.

P2860

Q28476705-55E347B2-A71C-4730-8E8B-1CFEA24651E9 Q28551971-62C3BA85-1CB7-4464-BCB9-2D49D6F23B2F Q30576597-B9B49BEB-011B-4601-936B-F5BED75636D1 Q30884443-A9994BD9-E186-464E-BAC4-4D94FD4BA5B2 Q33676366-5F70CF97-FCEF-4049-8CA5-5341A96C18C9 Q33798324-A003CFE9-2FDC-4135-A5B9-DCF333A4A4D3 Q33826267-C5FBF86E-9094-417A-A2BD-98D00C1A8123 Q33847509-02F8A8A4-7815-44CC-80D6-BE27240836C4 Q34108660-B5DA4E2B-2AE3-4866-942D-160A2A3B024E Q34320945-C51F4156-0D29-429E-A6F4-AB9A2BF05558 Q34652418-D880EE9F-4262-4B21-81BA-061A270421C5 Q34676586-7381DAAB-A4DB-4A82-8C1C-BB678F03D147 Q34922570-5D7E2CB1-0309-4CAA-811F-6E7FE45760BA Q35008357-D5ACC474-B82B-41DE-8A8C-F3D35A05FA46 Q35364351-3C41FEE8-2F6E-4074-AB7E-5A815F86C439 Q35432770-89AFEB87-8E46-49CE-ADAF-508EFE8ED71C Q35598403-C2495ABC-FE96-4CBC-82DB-8EB74FDB063D Q35941209-1109EE46-DF08-46AD-90D8-6DB68B426A93 Q36089663-6FF6E5AF-9DB3-459B-A797-7CEA633A727D Q36158501-A11CE7ED-ECE0-402C-B4A2-4B6413CDBD68 Q36172505-C740D457-CCCA-4FEB-895A-0A3363F332AE Q36255587-33B0E7C7-5CE7-4BE8-A4BB-BD8DE8297D25 Q36335694-0F145EF9-B607-4DE1-91A6-CF34E17A7933 Q36363261-EB8D5966-068D-424C-B9C6-50EC7BE67366 Q36593786-8A85660B-7EA2-46FB-AB05-22EC1A21119F Q36762991-C9E97A2D-3AA9-4275-A3CF-233BCD2BCBAE Q36887819-1231375C-1601-4285-AA0C-FD7EB4804929 Q36960059-BE600422-62E5-439C-9DC4-4CF7A47D7A5C Q37023206-69349C95-DC82-49B0-BF24-D11F1437D7A2 Q37069191-D5FD8F45-A42C-4A01-9F26-E88D7962323D Q37203872-1CDE623B-A31D-4864-B0B8-18482C123BB2 Q37215935-FE590A2D-55A6-4AE7-AC3E-FA789A960F08 Q37358781-C79351E2-1F74-45BB-9EE9-E8CB2EFAC05F Q37656243-B054777E-7B08-4312-863F-F0B6B6B9A7E3 Q37949391-D09FA59A-A9DE-4267-8B1C-9550567379A6 Q38586123-6B0889AD-2246-4333-834B-7D7DB9430C0E Q38613051-A3E0A722-A0B5-41F6-A6E9-787571B2B6AE Q38994000-58D2403B-4102-47E0-AA98-110ABFF403E5 Q39293585-841562BF-0181-4712-8887-FD8F52EEBB4E Q40035349-D990D9D1-7FB9-4F8F-B292-2FAC997E9544

P2860

Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa.

http://www.wikidata.org/entity/Q33935368

description

2005 nî lūn-bûn

@nan

2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa.

@ast

Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa.

@en

type

label

Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa.

@ast

Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa.

@en

prefLabel

Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa.

@ast

Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa.

@en

P1433

Q33935368-A39A7F25-4FE0-48C8-B29A-A43298447BC4

P1476

Q33935368-90FFF269-90B0-4060-B037-D8AA41CD52CE

P2093

Q33935368-0B6473EB-9FF3-478F-95DB-A5D160E355A6

Q33935368-BA141AF0-96C9-4C95-82C2-7DE9DA1B9C13

Q33935368-D0526720-4196-42A8-91A1-67961D337EFF

Q33935368-E5CEA944-62A3-44D4-8893-A37056DD8AEE

Q33935368-ECC28860-3005-4324-8391-DFC079C20AAB

P2860

Q33935368-01D2C3F5-060F-4185-8274-90E9FE5A6DBC

Q33935368-0C16BAA5-EC85-42F5-A6C3-6D1EBE322F20

Q33935368-24577C07-EB18-4F2E-8A2E-1C2AD11AE7AE

Q33935368-2D9488A7-5683-48AE-A8FF-7964278C4CA2

Q33935368-3ADBDB46-454C-4E53-B75C-DC7EB7959484

Q33935368-582910AD-DA73-4150-9E17-5D4AD9B2EF5C

Q33935368-5B21445B-D95A-491E-974F-9FAA9E18696F

Q33935368-5BCF0C81-5C92-4ACB-A836-ED9E994F53CB

Q33935368-5FB9F395-89A3-4AAA-B765-13437476873B

Q33935368-62047DE3-A7BF-47F4-9922-3D219E315EBA

P304

Q33935368-C693974E-2C16-457C-ACB9-D488A2052864

P31

Q33935368-40668A55-8853-424C-9BF3-26B9D0A751AC

P356

Q33935368-F5A014FF-E5AB-4B18-81EE-AF201CFBECD6

P407

Q33935368-64C53D6E-767A-42B7-BF31-430CF3563073

P433

Q33935368-B071A8EF-792F-4E05-B6F4-705792774AAD

P478

Q33935368-1E6735EA-984C-4E1C-9C08-502E553C4A54

P50

Q33935368-99D29111-3F83-48AF-ADD1-6410C9DA0FBB

Q33935368-F09E798C-813D-451C-A788-391F8679919B

P577

Q33935368-2A801C1E-3892-41C5-9EDD-C3573C25D253

P698

Q33935368-B88F1FE1-9E7D-4BBC-956D-2D851D098A2C

P921

Q33935368-1C1AB1D1-9AF0-4B26-A5C5-198D863C050A

P932

Q33935368-15BEB09D-410F-4526-A202-F31CC2AAB1A2

P356

AAC.49.9.3624-3630.2005

P1433

Antimicrobial Agents and Chemotherapy

P1476

Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa

@en

P2093

Amy N Schilling

http://www.w3.org/2001/XMLSchema#string

Andrea L Kwa

http://www.w3.org/2001/XMLSchema#string

Giao Vo

http://www.w3.org/2001/XMLSchema#string

Samer Kabbara

http://www.w3.org/2001/XMLSchema#string

Vincent H Tam

http://www.w3.org/2001/XMLSchema#string

P2860

Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients

Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria.

Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'.

Inhibition of lipopolysaccharide-initiated activation of serum complement by polymyxin B

Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria

Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications.

Effect of 2',3'-didehydro-3'-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies.

Random amplified polymorphic DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis

National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002.

Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin.

P304

3624-3630

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.49.9.3624-3630.2005

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P50

Russell E. Lewis

Nathan P. Wiederhold

P577

2005-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16127031

http://www.w3.org/2001/XMLSchema#string

P921

Pseudomonas aeruginosa

P932

1195418

http://www.w3.org/2001/XMLSchema#string